Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population

dc.contributorVillegas, María Virginia [0000-0003-1898-9067]
dc.creatorTamma , Pranita
dc.creatorVillegas, María Virginia
dc.date.accessioned2020-07-15T20:51:25Z
dc.date.accessioned2023-06-05T14:56:38Z
dc.date.available2020-07-15T20:51:25Z
dc.date.available2023-06-05T14:56:38Z
dc.date.created2020-07-15T20:51:25Z
dc.date.issued2017
dc.identifier1098-6596
dc.identifierhttp://hdl.handle.net/20.500.12495/3503
dc.identifierhttps://doi.org/10.1128/AAC.01094-17
dc.identifierinstname:Universidad El Bosque
dc.identifierreponame:Repositorio Institucional Universidad El Bosque
dc.identifierhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/6642990
dc.languageeng
dc.publisherAmerican Society for Microbiology
dc.publisherAntimicrobial agents and chemotherapy
dc.relationAntimicrobial agents and chemotherapy, 1098-6596, Vol. 61, Nro. 8, 2017
dc.relationhttps://aac.asm.org/content/61/8/e01094-17
dc.rightsAcceso abierto
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAcceso abierto
dc.rights2017-06-05
dc.titleUse of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population


Este ítem pertenece a la siguiente institución